Pär-Ola Bendahl - Search Results

Year	Number of Results
2002	5
2003	9
2004	3
2005	5
2006	2
2007	10
2008	7
2009	11
2010	9
2011	9
2012	9
2013	14
2014	5
2015	12
2016	7
2017	9
2018	7
2019	7
2020	11
2021	3
2022	6
2023	8
2024	3

1

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.

Lundgren C, Tutzauer J, Church SE, Stål O, Ekholm M, Forsare C, Nordenskjöld B, Fernö M, Bendahl PO, Rydén L. Lundgren C, et al. Among authors: bendahl po. Breast Cancer Res. 2023 Sep 29;25(1):110. doi: 10.1186/s13058-023-01719-z. Breast Cancer Res. 2023. PMID: 37773134 Free PMC article.

2

Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.

Gunnarsdottir FB, Bendahl PO, Johansson A, Benfeitas R, Rydén L, Bergenfelz C, Larsson AM. Gunnarsdottir FB, et al. Among authors: bendahl po. Breast Cancer Res. 2023 Mar 21;25(1):29. doi: 10.1186/s13058-023-01631-6. Breast Cancer Res. 2023. PMID: 36945037 Free PMC article.

3

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.

Lundgren C, Bendahl PO, Church SE, Ekholm M, Fernö M, Forsare C, Krüger U, Nordenskjöld B, Stål O, Rydén L. Lundgren C, et al. Among authors: bendahl po. NPJ Breast Cancer. 2022 May 9;8(1):61. doi: 10.1038/s41523-022-00423-z. NPJ Breast Cancer. 2022. PMID: 35534504 Free PMC article.

4

Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial.

Egelberg M, De Marchi T, Pekar G, Tran L, Bendahl PO, Tullberg AS, Holmberg E, Karlsson P, Farnebo M, Killander F, Nimeús E. Egelberg M, et al. Among authors: bendahl po. Mol Oncol. 2023 Oct;17(10):2029-2040. doi: 10.1002/1878-0261.13426. Epub 2023 Apr 19. Mol Oncol. 2023. PMID: 36975842 Free PMC article. Clinical Trial.

5

Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation.

Evans CE, Bendahl PO, Belting M, Branco C, Johnson RS. Evans CE, et al. Among authors: bendahl po. Blood. 2016 Mar 10;127(10):1355-60. doi: 10.1182/blood-2015-09-671982. Epub 2015 Dec 23. Blood. 2016. PMID: 26702059 Free PMC article.

6

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.

Jørgensen CLT, Forsare C, Bendahl PO, Falck AK, Fernö M, Lövgren K, Aaltonen K, Rydén L. Jørgensen CLT, et al. Among authors: bendahl po. Breast Cancer Res Treat. 2020 Jun;181(2):369-381. doi: 10.1007/s10549-020-05627-0. Epub 2020 Apr 16. Breast Cancer Res Treat. 2020. PMID: 32300922 Free PMC article.

7

Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Kimbung S, Chang CY, Bendahl PO, Dubois L, Thompson JW, McDonnell DP, Borgquist S. Kimbung S, et al. Among authors: bendahl po. Endocr Relat Cancer. 2017 Jul;24(7):339-349. doi: 10.1530/ERC-16-0533. Epub 2017 Apr 25. Endocr Relat Cancer. 2017. PMID: 28442559

8

Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN-A Randomized Trial with Low Molecular Weight Heparin.

Bendahl PO, Belting M, Gezelius E. Bendahl PO, et al. Cancers (Basel). 2023 Jun 13;15(12):3176. doi: 10.3390/cancers15123176. Cancers (Basel). 2023. PMID: 37370786 Free PMC article.

9

RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer.

Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J. Staaf J, et al. Among authors: bendahl po. NPJ Breast Cancer. 2022 Aug 16;8(1):94. doi: 10.1038/s41523-022-00465-3. NPJ Breast Cancer. 2022. PMID: 35974007 Free PMC article.

10

The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer.

Skarping I, Nilsson K, Dihge L, Fridhammar A, Ohlsson M, Huss L, Bendahl PO, Steen Carlsson K, Rydén L. Skarping I, et al. Among authors: bendahl po. Breast Cancer Res Treat. 2022 Aug;194(3):577-586. doi: 10.1007/s10549-022-06636-x. Epub 2022 Jul 5. Breast Cancer Res Treat. 2022. PMID: 35790694 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

157 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year